Breaking News Instant updates and real-time market news.

HALO

Halozyme

$15.93

0.8 (5.29%)

07:23
01/11/19
01/11
07:23
01/11/19
07:23

Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo

Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.

  • 28

    Jan

HALO Halozyme
$15.93

0.8 (5.29%)

10/18/18
PIPR
10/18/18
INITIATION
Target $17
PIPR
Neutral
Halozyme assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Halozyme Therapeutics with a Neutral rating and $17 price target. While the analyst views the Enhanze technology as an "attractive platform that could drive substantial royalty revenue," he has near term concerns around the pivotal HALO-301 study. He believes HALO-301 will need to hit on both progression-free survival and overall survival to support approval and adoption, which tempers his expectations.
11/27/18
CANT
11/27/18
NO CHANGE
Target $27
CANT
Overweight
Halozyme modified Phase 3 design 'a good thing,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating and $27 price target on Halozyme Therapeutics after the company announced that it has made a request to the FDA to change the dual primary endpoints of progression free survival and overall survival of the HALO-301 study to the single primary endpoint of overall survival. On the surface, this "change" can quickly lead to a negative perception of trial progress, Duncan tells investors in a research note titled "Don't Miss the Forest for the Trees - Modified P3 is a Good Thing." However, when assessing the design and rationale, in conjunction with the study remaining blinded, the analyst views the move as "prudent, with the clinical risk thus having been reduced, at least, incrementally." He believes investors appreciate the high-risk in pancreatic cancer, and therefore see low expectations for Phase 3 success being priced into the current share price. Duncan says he has "enhanced non-zero conviction" in the potential for HALO-301 to read out positively in the second half of 2019.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/22/19
02/22
14:17
02/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/22/19
02/22
14:16
02/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUFG

Mitsubishi UFJ

$5.27

-0.02 (-0.38%)

14:15
02/22/19
02/22
14:15
02/22/19
14:15
Hot Stocks
OCC issues cease and desist order against MUFG Bank over BSA violation »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

XOG

Extraction Oil & Gas

$4.64

0.83 (21.78%)

14:13
02/22/19
02/22
14:13
02/22/19
14:13
Recommendations
Extraction Oil & Gas analyst commentary  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares China Large-Cap ETF

$44.14

0.73 (1.68%)

14:10
02/22/19
02/22
14:10
02/22/19
14:10
Options
Size option spreads in iShares China Fund as the trade-hope rally continues »

Size option spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:09
02/22/19
02/22
14:09
02/22/19
14:09
Periodicals
China, U.S. remain far apart on intellectual property transfer, CNBC reports »

China has committed to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRN

Citi Trends

$20.69

0.28 (1.37%)

14:06
02/22/19
02/22
14:06
02/22/19
14:06
Initiation
Citi Trends initiated  »

Citi Trends initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

  • 15

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

China agrees to buy $1.2…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNK

Cinemark

$38.52

1.58 (4.28%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Recommendations
Cinemark analyst commentary  »

Cinemark Q4 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 11

    Mar

  • 02

    Apr

  • 02

    Apr

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

U.S., China remain far…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$52.93

0.58 (1.11%)

14:00
02/22/19
02/22
14:00
02/22/19
14:00
Options
Qualcomm calls lead puts 4:1 »

Qualcomm calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 12

    Mar

NVS

Novartis

$90.83

0.32 (0.35%)

, BIIB

Biogen

$324.70

3.71 (1.16%)

13:58
02/22/19
02/22
13:58
02/22/19
13:58
Periodicals
Novartis SMA therapy Zolgensma cost effective at up to $900,000, Reuters reports »

Zolgensma, an…

NVS

Novartis

$90.83

0.32 (0.35%)

BIIB

Biogen

$324.70

3.71 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 11

    Mar

  • 12

    Mar

  • 19

    Mar

  • 28

    May

BRQS

Borqs Technologies

$4.00

(0.00%)

13:48
02/22/19
02/22
13:48
02/22/19
13:48
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRQS

Borqs Technologies

$4.00

(0.00%)

13:43
02/22/19
02/22
13:43
02/22/19
13:43
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$278.85

1.42 (0.51%)

, XLF

Financial Select Sector

$26.44

-0.07 (-0.26%)

13:41
02/22/19
02/22
13:41
02/22/19
13:41
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week, ETF fund…

SPY

SPDR S&P 500 ETF Trust

$278.85

1.42 (0.51%)

XLF

Financial Select Sector

$26.44

-0.07 (-0.26%)

XLB

S&P Select Materials SPDR

$55.79

0.25 (0.45%)

BSV

Vanguard Short-Term Bond Index Fund

$78.99

0.11 (0.14%)

BIV

Vanguard Intermediate-Term Bond ETF

$82.51

0.285 (0.35%)

BLV

Vanguard Long-Term Bond ETF

$89.00

0.685 (0.78%)

IEF

iShares 7-10 Year Treasury Bond ETF

$104.65

0.35 (0.34%)

QQQ

Invesco QQQ Trust

$172.67

1.06 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$162.16

2.09 (1.31%)

13:40
02/22/19
02/22
13:40
02/22/19
13:40
Periodicals
NY Governor asks for probe of Facebook use of personal info, Bloomberg says »

New York Governor Andrew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

WEX

Wex

$176.23

5.88 (3.45%)

13:33
02/22/19
02/22
13:33
02/22/19
13:33
Earnings
Wex sees 2019 adjusted EPS $8.80-$9.20, consensus $8.94 »

Sees 2019 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.23

5.88 (3.45%)

13:32
02/22/19
02/22
13:32
02/22/19
13:32
Earnings
Wex reported preliminary 2018 adjusted EPS $8.18, consensus $8.18 »

Reported preliminary 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.24

5.89 (3.46%)

13:29
02/22/19
02/22
13:29
02/22/19
13:29
Hot Stocks
Wex delays earnings on up to $70M Brazilian subsidiary discrepancy »

Wex announced earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.53

6.18 (3.63%)

13:26
02/22/19
02/22
13:26
02/22/19
13:26
Periodicals
Wex CEO tells Bloomberg business 'incredibly healthy' despite Brazil issue »

WEX's overall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
Xerox rating change  »

Xerox downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.55

0.75 (0.84%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
United Continental rating change  »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.89

1.46 (0.53%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Periodicals
U.S, China disusing late March summit between Xi and Trump, CNBC reports »

U.S. and China are…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.89

1.46 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$33.90

0.29 (0.86%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
Skechers rating change  »

Skechers downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

DXCM

DexCom

$139.14

-7.14 (-4.88%)

13:17
02/22/19
02/22
13:17
02/22/19
13:17
Hot Stocks
DexCom receives Health Canada approval for G6 CGM System »

Dexcom announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.